{"id":"NCT01412424","sponsor":"Chiasma, Inc.","briefTitle":"Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly","officialTitle":"Efficacy and Safety of Oral Octreolin™ in Patients With Acromegaly Who Are Currently Receiving Parenteral Somatostatin Analogs","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-03","primaryCompletion":"2014-05","completion":"2014-05","firstPosted":"2011-08-09","resultsPosted":"2015-12-01","lastUpdate":"2017-08-17"},"enrollment":155,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acromegaly"],"interventions":[{"type":"DRUG","name":"Octreotide capsules","otherNames":["MYCAPSSA™","Formerly known as Octreolin™"]}],"arms":[{"label":"Octreotide capsules","type":"EXPERIMENTAL"}],"summary":"MYCAPSSA™ (formerly Octreolin™) is a proprietary oral form of the approved injectable medical product octreotide used to treat acromegaly. This study will evaluate the efficacy and safety of MYCAPSSA™ treatment in patients with acromegaly.","primaryOutcome":{"measure":"Percentage of Responders at the End of the Core Treatment Period","timeFrame":"End of the core treatment period (up to 7 months)","effectByArm":[{"arm":"Octreotide 40 mg","deltaMin":86.9,"sd":null},{"arm":"Octreotide 60 mg","deltaMin":66.7,"sd":null},{"arm":"Octreotide 80 mg","deltaMin":40.4,"sd":null},{"arm":"Octreotide 40, 60, or 80 mg - All Participants","deltaMin":64.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":11},"locations":{"siteCount":36,"countries":["United States","Germany","Hungary","Italy","Lithuania","Mexico","Netherlands","Poland","Romania","Serbia","Slovakia","Slovenia","United Kingdom"]},"refs":{"pmids":["34173129","25664604"],"seeAlso":["http://www.chiasmapharma.com"]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":155},"commonTop":["Headache","Arthralgia","Nausea","Asthenia","Hyperhidrosis"]}}